The influences of risk scores on immune-oncological targets (PD1, CTLA4, and CD19), immunoscore, and immune cell infiltration were then assessed, thus revealing the effect of the butyrate metabolism on ccRCC TIME. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.